{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:15Z","timestamp":1792533615869,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100021083","name":"Society for Pediatric Anesthesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.diabres.2025.112244","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:55:31Z","timestamp":1746795331000},"page":"112244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study"],"prefix":"10.1016","volume":"224","author":[{"given":"Alessandro","family":"Rizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-2691","authenticated-orcid":false,"given":"Monica","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-4418","authenticated-orcid":false,"given":"Maura","family":"Brioschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Banfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-9040","authenticated-orcid":false,"given":"Stefano","family":"Lancellotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo De","family":"Cristofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-686X","authenticated-orcid":false,"given":"Dario","family":"Pitocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.diabres.2025.112244_b0005","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/ATVBAHA.120.315754","article-title":"Thrombus structural composition in cardiovascular disease","volume":"41","author":"Alkarithi","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4 Suppl.","key":"10.1016\/j.diabres.2025.112244_b0010","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2025.112244_b0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.diabres.2025.112244_b0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112244_b0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.diabres.2025.112244_b0035","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/cvr\/cvaa263","article-title":"Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment","volume":"117","author":"Ten Cate","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.diabres.2025.112244_b0045","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"2_suppl","key":"10.1016\/j.diabres.2025.112244_b0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/2047487319880045","article-title":"Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease","volume":"26","author":"Rocca","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"10.1016\/j.diabres.2025.112244_b0055","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Davi","year":"1990","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2025.112244_b0060","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabres.2025.112244_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01244","article-title":"Measurement of thromboxane biosynthesis in health and disease","volume":"10","author":"Patrono","year":"2019","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.diabres.2025.112244_b0070","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1111\/bph.12677","article-title":"Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation","volume":"171","author":"Bauer","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"24","key":"10.1016\/j.diabres.2025.112244_b0075","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2025.112244_b0080","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2004-07-2698","article-title":"Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP","volume":"107","author":"Cleator","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.diabres.2025.112244_b0085","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2025.112244_b0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11239-023-02776-z","article-title":"The effect of rivaroxaban on biomarkers in blood and plasma: a review of preclinical and clinical evidence","volume":"55","author":"Schiffer","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.diabres.2025.112244_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediators Inflamm"},{"issue":"10","key":"10.1016\/j.diabres.2025.112244_b0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.105.574830","article-title":"Protease-activated receptors in cardiovascular diseases","volume":"114","author":"Leger","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.diabres.2025.112244_b0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2125.1998.00766.x","article-title":"The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils","volume":"46","author":"Taylor","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.diabres.2025.112244_b0110","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1161\/01.CIR.102.16.1924","article-title":"Participation of tyrosine phosphorylation in cytoskeletal reorganization, alpha(IIb)beta(3) integrin receptor activation, and aspirin-insensitive mechanisms of thrombin-stimulated human platelets","volume":"102","author":"Santos","year":"2000","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2025.112244_b0115","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0120","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/s41598-024-55720-3","article-title":"Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B(2) and 8-iso-prostaglandin F(2alpha,) levels in human urine samples by validated enzyme immunoassays","volume":"14","author":"Petrucci","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.diabres.2025.112244_b0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2022.04.034","article-title":"Association of thromboxane generation with survival in aspirin users and nonusers","volume":"80","author":"Rade","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112244_b0130","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/cvr\/cvab003","article-title":"The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112244_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031136","article-title":"An optimized MRM-based workflow of the l-arginine\/nitric oxide pathway metabolites revealed disease- and sex-related differences in the cardiovascular field","volume":"23","author":"Porro","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1515\/bmc-2019-0022","article-title":"Mechanochemistry of von Willebrand factor","volume":"10","author":"Lancellotti","year":"2019","journal-title":"Biomol Concepts"},{"issue":"4","key":"10.1016\/j.diabres.2025.112244_b0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032835","article-title":"Urinary prostaglandin E2 excretion and the risk of cardiovascular and kidney disease","volume":"13","author":"Geurts","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.diabres.2025.112244_b0150","article-title":"Role of oxidative stress in the pathogenesis of atherothrombotic diseases","volume":"11","author":"Petrucci","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0155","first-page":"118","article-title":"In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia","volume":"112","author":"Cavalca","year":"2014","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.diabres.2025.112244_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102623","article-title":"Stability of the thromboxane B(2) biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples","volume":"8","author":"Petrucci","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ab.2011.01.018","article-title":"Quantification of arginine and its metabolites in human erythrocytes using liquid chromatography-tandem mass spectrometry","volume":"412","author":"Squellerio","year":"2011","journal-title":"Anal Biochem"},{"issue":"6","key":"10.1016\/j.diabres.2025.112244_b0170","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/jth.15292","article-title":"Thrombin generation measured by two platforms in patients with a bleeding tendency","volume":"19","author":"Cornette","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.96.1.69","article-title":"Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease","volume":"96","author":"Davi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2025.112244_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.phrs.2013.05.002","article-title":"The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure","volume":"74","author":"Flierl","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabres.2025.112244_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.684920","article-title":"Soluble platelet release factors as biomarkers for cardiovascular disease","volume":"8","author":"Baidildinova","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112244_b0190","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11239-017-1495-z","article-title":"Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation","volume":"43","author":"Steppich","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"15","key":"10.1016\/j.diabres.2025.112244_b0195","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/eurheartj\/ehad868","article-title":"Thromboxane biosynthesis and future events in diabetes: the ASCEND trial","volume":"45","author":"Petrucci","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2025.112244_b0200","doi-asserted-by":"crossref","DOI":"10.5414\/CP204335","article-title":"Comparative pharmacokinetics of two formulations of 2.5-mg rivaroxaban in healthy Korean subjects","author":"Moon","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.diabres.2025.112244_b0205","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1021\/jm050101d","article-title":"Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor","volume":"48","author":"Roehrig","year":"2005","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/bcp.13429","article-title":"Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation","volume":"84","author":"Horinaka","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2162-3619-3-30","article-title":"Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release","volume":"3","author":"Laurent","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112244_b0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1160\/TH11-04-0275","article-title":"Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells","volume":"106","author":"Rosenkranz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.diabres.2025.112244_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086491","article-title":"Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model","volume":"9","author":"Hosokawa","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.diabres.2025.112244_b0230","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.diabres.2025.112244_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.979819","article-title":"Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial","volume":"9","author":"Willems","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.diabres.2025.112244_b0240","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.amjcard.2018.07.032","article-title":"D-dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (an ATLAS ACS-TIMI 46 trial substudy)","volume":"122","author":"AlKhalfan","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2025.112244_b0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2022.05.017","article-title":"The effect of rivaroxaban on the diagnostic value of D-dimer in patients with suspected deep vein thrombosis","volume":"216","author":"Mohamad","year":"2022","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112244_b0250","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.thromres.2013.09.033","article-title":"Age- and sex-dependent reference intervals for D-dimer: evidence for a marked increase by age","volume":"132","author":"Haase","year":"2013","journal-title":"Thromb Res"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272500258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272500258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:51:29Z","timestamp":1778388689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272500258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":50,"alternative-id":["S016882272500258X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112244","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112244"}}